Tumor cell-free DNA detection-based liquid biopsy of plasma and bile in pancreatic ductal adenocarcinoma: a pilot study

Abstract

INTRODUCTION: Plasma liquid biopsy with tumor cell-free DNA detection is one of the most promising technologies in pancreatic ductal adenocarcinoma diagnosis. Due to low levels of this biomarker in plasma its detectability turns out to be lower than expected. However, some patients with this disease present with biliary obstruction, which enables collection of bile for tumor cell-free DNA analysis.

THE AIM: To comparison of diagnostic potential of cell-free tumor DNA detection-based liquid biopsy of plasma and bile in pancreatic ductal adenocarcinoma patients.

MATERIAL AND METHODS: The pilot study included 15 primary untreated pancreatic ductal adenocarcinoma patients with biliary obstruction. Cell-free DNA was isolated from 5 mL of plasma and 5 mL of bile. Tumor cell-free DNA detection was performed using digital droplet PCR with KRAS gene mutations analysis: G12A, G12C, G12D, G12R, G12S, G12V, G13D и Q61H (183A>C), Q61H (183A>T), Q61K, Q61L, Q61R. False-positive droplets threshold was established during the analysis of plasma cell-free DNA samples from 15 healthy volunteers.

RESULTS: Tumor cell-free DNA was detected in 13 out of 15 bile samples, whereas among paired plasma samples only 9 were positive. All plasma positive samples had a paired positive bile sample. Tumor cell-free DNA levels were statistically significantly higher in bile than in plasma: 538.0 (4.1–1960.0) vs. 4.4 (0–27.6) copies/mL (p=0.005).

CONCLUSION: Bile liquid biopsy in pancreatic ductal adenocarcinoma patients with biliary obstruction is a promising alternative to plasma analysis, due to higher concentrations of tumor cell-free DNA.

Keywords

liquid biopsy / cell-free DNA / digital droplet PCR / pancreatic ductal adenocarcinoma / bile / tumor DNA

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660

[2] Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2021. Vol. 71, N 3. P. 209–249. doi: 10.3322/caac.21660

[3] Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10(1):16425. doi: 10.1038/s41598-020-73525-y

[4] Bengtsson A., Andersson R., Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data // Sci Rep. 2020. Vol. 10, N 1. P. 16425. doi: 10.1038/s41598-020-73525-y

[5] Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(9):2913–2921.

[6] Rahib L., Smith B.D., Aizenberg R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States // Cancer Res. 2014. Vol. 74, N 9. P. 2913–2921.

[7] Jain M, Nekrasova LA, Meshcheriakov OA, et al. Liquid biopsy as a tool for tumor growth and metastasis formation control. Technologies of Living Systems. 2021;18(4):21–33. (In Russ). doi: 10.18127/j20700997-202104-02

[8] Джайн М., Некрасова Л.A., Мещеряков О.A., и др. Жидкостная биопсия как инструмент контроля роста и метастазирования опухоли // Технологии живых систем. 2021. Т. 18, № 4. С. 21–33. doi: 10.18127/j20700997-202104-02

[9] Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–D947. doi: 10.1093/nar/gky1015

[10] Tate J.G., Bamford S., Jubb H.C., et al. COSMIC: the catalogue of somatic mutations in cancer // Nucleic Acids Res. 2019. Vol. 47, N D1. P. D941–D947. doi: 10.1093/nar/gky1015

[11] Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77. doi: 10.5114/wo.2014.47136

[12] Tomczak K., Czerwińska P., Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge // Contemp Oncol (Pozn). 2015. Vol. 19, N 1A. P. A68–A77. doi: 10.5114/wo.2014.47136

[13] Zhu Y, Zhang H, Chen N, et al. Diagnostic value of various liquid biopsy methods for pancreatic cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99(3):e18581. doi: 10.1097/MD.0000000000018581

[14] Zhu Y., Zhang H., Chen N., et al. Diagnostic value of various liquid biopsy methods for pancreatic cancer: a systematic review and meta-analysis // Medicine (Baltimore). 2020. Vol. 99, N 3. P. e18581. doi: 10.1097/MD.0000000000018581

[15] Modolell I, Guarner L, Malagelada JR. Vagaries of clinical presentation of pancreatic and biliary tract cancer. Ann Oncol. 1999;10 suppl. 4:82–84.

[16] Modolell I., Guarner L., Malagelada J.R. Vagaries of clinical presentation of pancreatic and biliary tract cancer // Ann Oncol. 1999. Vol. 10 (suppl. 4). P. 82–84.

[17] Distler M, Kersting S, Rückert F, et al. Palliative treatment of obstructive jaundice in patients with carcinoma of the pancreatic head or distal biliary tree. Endoscopic stent placement vs. hepaticojejunostomy. JOP. 2010;11(6):568–574.

[18] Distler M., Kersting S., Rückert F., et al. Palliative treatment of obstructive jaundice in patients with carcinoma of the pancreatic head or distal biliary tree. Endoscopic stent placement vs. hepaticojejunostomy // JOP. 2010. Vol. 11, N 6. P. 568–574.

[19] La Rocca F, Grieco V, Ruggieri V, et al. Superiority of droplet digital PCR over real-time quantitative PCR for JAK2 V617F allele mutational burden assessment in myeloproliferative neoplasms: a retrospective study. Diagnostics (Basel). 2020;10(3):143. doi: 10.3390/diagnostics10030143

[20] La Rocca F., Grieco V., Ruggieri V., et al. Superiority of droplet digital PCR over real-time quantitative PCR for JAK2 V617F allele mutational burden assessment in myeloproliferative neoplasms: a retrospective study // Diagnostics (Basel). 2020. Vol. 10, N 3. P. 143. doi: 10.3390/diagnostics10030143

[21] Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid biopsy in pancreatic cancer: are we ready to apply it in the clinical practice? Cancers (Basel). 2021;13(8):1986. doi: 10.3390/cancers13081986

[22] Heredia-Soto V., Rodríguez-Salas N., Feliu J. Liquid biopsy in pancreatic cancer: are we ready to apply it in the clinical practice? // Cancers (Basel). 2021. Vol. 13, N 8. P. 1986. doi: 10.3390/cancers13081986

[23] Shaw KJ, Thain L, Docker PT, et al. The use of carrier RNA to enhance DNA extraction from microfluidic-based silica monoliths. Anal Chim Acta. 2009;652(1-2):231–233. doi: 10.1016/j.aca.2009.03.038

[24] Shaw K.J., Thain L., Docker P.T., et al. The use of carrier RNA to enhance DNA extraction from microfluidic-based silica monoliths // Anal Chim Acta. 2009. Vol. 652, N 1-2. P. 231–233. doi: 10.1016/j.aca.2009.03.038

[25] Smania MA. Liquid biopsy for cancer screening, diagnosis, and treatment. J Am Assoc Nurse Pract. 2020;32(1):5–7. doi: 10.1097/JXX.0000000000000359

[26] Smania M.A. Liquid biopsy for cancer screening, diagnosis, and treatment // J Am Assoc Nurse Pract. 2020. Vol. 32, N 1. P. 5–7. doi: 10.1097/JXX.0000000000000359

[27] Uhe I, Hagen ME, Ris F, et al. Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: a systematic review. World J Gastrointest Oncol. 2021;13(11):1799–1812. doi: 10.4251/wjgo.v13.i11.1799

[28] Uhe I., Hagen M.E., Ris F., et al. Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: a systematic review // World J Gastrointest Oncol. 2021. Vol. 13, N 11. P. 1799–1812. doi: 10.4251/wjgo.v13.i11.1799

[29] Hosen MI, Sheikh M, Zvereva M, et al. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: evidence from the Golestan Cohort Study. EBioMedicine. 2020;53:102643. doi: 10.1016/j.ebiom.2020.102643

[30] Hosen M.I., Sheikh M., Zvereva M., et al. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: evidence from the Golestan Cohort Study // EBioMedicine. 2020. Vol. 53. P. 102643. doi: 10.1016/j.ebiom.2020.102643

[31] Gou Q, Zhang CZ, Sun ZH, et al. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer. ESMO Open. 2021;6(6):100275. doi: 10.1016/j.esmoop.2021.100275

[32] Gou Q., Zhang C.Z., Sun Z.H., et al. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer // ESMO Open. 2021. Vol. 6, N 6. P. 100275. doi: 10.1016/j.esmoop.2021.100275

[33] Driescher C, Fuchs K, Haeberle L, et al. Bile-based cell-free DNA analysis is a reliable diagnostic tool in pancreatobiliary cancer. Cancers (Basel). 2020;13(1):39. doi: 10.3390/cancers13010039

[34] Driescher C., Fuchs K., Haeberle L., et al. Bile-based cell-free DNA analysis is a reliable diagnostic tool in pancreatobiliary cancer // Cancers (Basel). 2020. Vol. 13, N 1. P. 39. doi: 10.3390/cancers13010039

[35] Kruse E. Palliation in pancreatic cancer. Surg Clin North Am. 2010;90(2):355–364. doi: 10.1016/j.suc.2009.12.004

[36] Kruse E. Palliation in pancreatic cancer // Surg Clin North Am. 2010. Vol. 90, N 2. P. 355–364. doi: 10.1016/j.suc.2009.12.004

[37] Mizuide M, Ryozawa S, Fujita A, et al. Complications of endoscopic ultrasound-guided fine needle aspiration: a narrative review. Diagnostics (Basel). 2020;10(11):964. doi: 10.3390/diagnostics10110964

[38] Mizuide M., Ryozawa S., Fujita A., et al. Complications of endoscopic ultrasound-guided fine needle aspiration: a narrative review // Diagnostics (Basel). 2020. Vol. 10, N 11. P. 964. doi: 10.3390/diagnostics10110964

[39] Nakatsubo R, Yamamoto K, Itoi T, et al. Histopathological evaluation of needle tract seeding caused by EUS-fine-needle biopsy based on resected specimens from patients with solid pancreatic masses: an analysis of 73 consecutive cases. Endosc Ultrasound. 2021;10(3):207–213. doi: 10.4103/EUS-D-20-00174

[40] Nakatsubo R., Yamamoto K., Itoi T., et al. Histopathological evaluation of needle tract seeding caused by EUS-fine-needle biopsy based on resected specimens from patients with solid pancreatic masses: an analysis of 73 consecutive cases // Endosc Ultrasound. 2021. Vol. 10, N 3. P. 207–213. doi: 10.4103/EUS-D-20-00174

[41] Hart P, Topazian M, Raimondo M, et al. Endoscopic pancreas fluid collection: methods and relevance for clinical care and translational science. Am J Gastroenterol. 2016;111(9):1258–1266. doi: 10.1038/ajg.2016.297

[42] Hart P., Topazian M., Raimondo M., et al. Endoscopic pancreas fluid collection: methods and relevance for clinical care and translational science // Am J Gastroenterol. 2016. Vol. 111, N 9. P. 1258–1266. doi: 10.1038/ajg.2016.297

[43] Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. 2021;48(1):10–18. doi: 10.1053/j.seminoncol.2021.02.003

[44] Luo J. KRAS mutation in pancreatic cancer // Semin Oncol. 2021. Vol. 48, N 1. P. 10–18. doi: 10.1053/j.seminoncol.2021.02.003

[45] Jain M, Kamalov D, Tivtikyan A, et al. Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: a pilot study. Mol Clin Oncol. 2021;15(6):253. doi: 10.3892/mco.2021.2415

[46] Jain M., Kamalov D., Tivtikyan A., et al. Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: a pilot study // Mol Clin Oncol. 2021. Vol. 15, N 6. P. 253. doi: 10.3892/mco.2021.2415

[47] Watanabe F, Suzuki K, Tamaki S, et al. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PloS One. 2019;14(12):e0227366. doi: 10.1371/journal.pone.0227366

[48] Watanabe F., Suzuki K., Tamaki S., et al. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer // PloS One. 2019. Vol. 14, N 12. P. e0227366. doi: 10.1371/journal.pone.0227366

[49] Ako S, Kato H, Nouso K, et al. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Cancer Biol Ther. 2021;22(10-12):564–570. doi: 10.1080/15384047.2021.1980312

[50] Ako S., Kato H., Nouso K., et al. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer // Cancer Biol Ther. 2021. Vol. 22, N 10-12. P. 564–570. doi: 10.1080/15384047.2021.1980312

[51] Del Re M, Vivaldi C, Rofi E, et al. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci Rep. 2017;7(1):7931. doi: 10.1038/s41598-017-08297-z

[52] Del Re M., Vivaldi C., Rofi E., et al. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer // Sci Rep. 2017. Vol. 7, N 1. P. 7931. doi: 10.1038/s41598-017-08297-z

RIGHTS & PERMISSIONS

Jain M., Atayan D.P., Rakhmatullin T.I., Dakhtler T.E., Popov P.A., Kim P.P., Gontareva J.V., Samokhodskaya L.M., Egorov V.I., Kamalov A.A.